Trending Topic

Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience
15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

Search Results

Showing Results for Clinical

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

As a touchNEUROLOGY Future Leader 2025, Dr Antonio Ciacciarelli shares what drew him to neurology, the lasting impact of mentorship, and why recent advances in stroke care are redefining outcomes. He reflects on the privilege of inspiring others, and the promise of neuroprotection as the next frontier in vascular neurology.

Mark CompleteCompleted
BookmarkBookmarked

Emerging data at EAN 2025 reveals key innovations across multiple neurological disease areas.

In this article, you will learn:

  1. Biomarkers are transforming dementia diagnosis with earlier and more accurate detection.
  2. CGRP-targeted therapies are advancing personalized migraine care.
  3. Wearables and digital tools are enhancing movement disorder monitoring.
  4. Data-driven decisions are improving stroke management and outcomes.
  5. Gene and molecular therapies are revolutionizing neuromuscular disease treatment.

Mark CompleteCompleted
BookmarkBookmarked
Coverage from: EAN 2025
Simona Sacco

Despite advances in targeted therapies, migraine remains a significant clinical burden.

In this Q&A, you will learn:

  1. How anti-CGRP therapies target migraine-specific pathways to deliver better efficacy and tolerability than traditional treatments.
  2. What real-world data reveal about patient response rates and rare but emerging side effects like Raynaud’s phenomenon.
  3. Why multiple delivery methods, such as oral, subcutaneous, and intravenous, enable higher adherence and more personalized migraine care.

Mark CompleteCompleted
BookmarkBookmarked

Prof. Simona Sacco outlines the European Stroke Organisation’s (ESO) strategic priorities to reduce disparities in stroke care across Europe. She discusses the transformative impact of the ESO East programme and the Stroke Action Plan for Europe (SAP-E), and also reflects on the increasing role of artificial intelligence (AI) in stroke diagnostics and treatment pathways.

43 mins
Sponsored Content

Watch leading experts discuss evolving fluid biomarkers for AD and assess current blood biomarkers for diagnosing AD in the clinic.

Mark CompleteCompleted
BookmarkBookmarked

Dr Bedia Samanci is a 2025 touchNEUROLOGY Future Leader, and is already making a significant impact in the field of clinical neurology. In this Q&A we discuss advanced neuroimaging, biomarker discovery and the integration of machine learning into neurological diagnostics. Areas that promise to shape the future of patient care.

Mark CompleteCompleted
BookmarkBookmarked

Prof. Michael Schöll joins us at EAN 2025, to discuss how plasma biomarkers are reshaping Alzheimer’s diagnostics, though not yet in routine clinical use.

In this Q&A, he explains the growing role of biomarkers like p-tau217 in MCI pathways, the challenges clinicians face without clear guidelines, and why blood-based and digital biomarkers, alongside new therapies, are the future of dementia care.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Dr Carolina Barnett-Tapia, Prof. Nils Erik Gilhus

Watch experts discuss strategies to accelerate MG diagnosis and treatment, plus consider emerging therapies.

Mark CompleteCompleted
BookmarkBookmarked

Prof. Joaquim Ferreira shares insights from EAN 2025 on the future of Parkinson’s disease care. He discusses realistic timelines for DMTs, the evolving role of gene therapy for genetic subgroups, and the potential of adaptive deep brain stimulation. Prof. Ferreira also highlights the growing importance of optimizing current treatments, interdisciplinary care, and addressing persistent challenges such as gait disturbance, dyskinesia, and cognitive decline.

Mark CompleteCompleted
BookmarkBookmarked

Prof. Bengt Winblad shares insights EAN 2025 on the evolving landscape of Alzheimer’s diagnosis and treatment. He discusses the growing role of biomarkers, the balance between early detection and clinical accuracy, and the challenges posed by the COVID-19 pandemic on dementia care. Prof. Winblad also explores emerging therapies, including monoclonal antibodies, and highlights the importance of combining biomarkers with cognitive testing to improve diagnostic precision and address the rise in undiagnosed cases post-pandemic.

Mark CompleteCompleted
BookmarkBookmarked
Coverage from: EAN 2025
Marcello Moccia

At EAN 2025, Prof. Moccia shared his perspective on the evolving multiple sclerosis McDonald criteria, the role of advanced imaging and fluid biomarkers, and the exciting innovations reshaping MS diagnosis and management.

Mark CompleteCompleted
BookmarkBookmarked

"Continued support for research, and for the patients themselves, is absolutely critical. I’m grateful for the opportunity to help bring some of this work to light." Dr Anissa Abi-Dargham is Chair of Psychiatry and Behavioral Health at the Renaissance ...

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.

Mark CompleteCompleted
BookmarkBookmarked

"I have learned to value meeting patients where they are, listening with empathy, and offering structure, which can build trust, strengthen compliance, and improve outcomes."   Dr Anna Maria Laure, postgraduate trainee in psychiatry and psychotherapy at the Medical University ...

Mark CompleteCompleted
BookmarkBookmarked

"it is great to find out that some reasoning and a prescription has helped someone turn their life around"   Dr Alexander Lisinski, resident psychiatrist at Sahlgrenska University Hospital and researcher at the Department of Pharmacology, Sahlgrenska Academy, Gothenburg, Sweden, ...

Mark CompleteCompleted
BookmarkBookmarked

Broadest approval to date in generalized myasthenia gravis The FDA approval of nipocalimab for generalized myasthenia gravis (gMG) introduces a targeted therapy within a validated class, offering the potential for durable disease control across the broadest patient population to date. ...

Load More...
Close Popup